Quanterix (NASDAQ:QTRX – Get Free Report) and Allurion Technologies (NYSE:ALUR – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.
Insider & Institutional Ownership
86.5% of Quanterix shares are owned by institutional investors. Comparatively, 21.4% of Allurion Technologies shares are owned by institutional investors. 1.5% of Quanterix shares are owned by insiders. Comparatively, 8.1% of Allurion Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Quanterix and Allurion Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Quanterix | -71.86% | -23.92% | -17.66% |
| Allurion Technologies | -199.96% | N/A | -77.13% |
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Quanterix | 1 | 2 | 0 | 0 | 1.67 |
| Allurion Technologies | 1 | 1 | 1 | 0 | 2.00 |
Quanterix presently has a consensus target price of $4.00, suggesting a potential upside of 29.03%. Allurion Technologies has a consensus target price of $3.00, suggesting a potential upside of 421.10%. Given Allurion Technologies’ stronger consensus rating and higher possible upside, analysts plainly believe Allurion Technologies is more favorable than Quanterix.
Risk and Volatility
Quanterix has a beta of 1.14, meaning that its share price is 14% more volatile than the S&P 500. Comparatively, Allurion Technologies has a beta of -0.13, meaning that its share price is 113% less volatile than the S&P 500.
Earnings and Valuation
This table compares Quanterix and Allurion Technologies”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Quanterix | $138.90 million | 1.05 | -$107.15 million | ($2.36) | -1.31 |
| Allurion Technologies | $17.21 million | 0.50 | -$7.20 million | ($2.03) | -0.28 |
Allurion Technologies has lower revenue, but higher earnings than Quanterix. Quanterix is trading at a lower price-to-earnings ratio than Allurion Technologies, indicating that it is currently the more affordable of the two stocks.
Summary
Allurion Technologies beats Quanterix on 8 of the 14 factors compared between the two stocks.
About Quanterix
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
About Allurion Technologies
Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. Allurion Technologies Inc. is headquartered in Natick, Massachusetts.
Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.
